skip to main content

H.R. 3520 (116th): Stem Cell Therapeutic and Research Reauthorization Act of 2019


The text of the bill below is as of Jun 26, 2019 (Introduced). The bill was not enacted into law.


I

116th CONGRESS

1st Session

H. R. 3520

IN THE HOUSE OF REPRESENTATIVES

June 26, 2019

(for himself and Mr. Bilirakis) introduced the following bill; which was referred to the Committee on Energy and Commerce

A BILL

To reauthorize the Stem Cell Therapeutic and Research Act of 2005, and for other purposes.

1.

Short title

This Act may be cited as the Stem Cell Therapeutic and Research Reauthorization Act of 2019.

2.

Reauthorization of the C.W. Bill Young Cell Transplantation Program

(a)

In general

Section 379(d)(2)(B) of the Public Health Service Act (42 U.S.C. 274k(d)(2)(B)) is amended—

(1)

by striking including remote collection, consistent with the inventory and inserting including collection, consistent with the inventory; and

(2)

by inserting including remote collection, before consistent with the requirements.

(b)

Advisory council meetings

Subsection (a) of section 379 of the Public Health Service Act (42 U.S.C. 274k) is amended by adding at the end the following new paragraph:

(7)

The Secretary shall convene the Advisory Council at least two times each calendar year.

.

(c)

Authorization of appropriations

Section 379B of the Public Health Service Act (42 U.S.C. 274m) is amended by striking $33,000,000 for fiscal year 2015 and $30,000,000 for each of fiscal years 2016 through 2020 and inserting $30,000,000 for each of fiscal years 2020 through 2024.

3.

Cord blood inventory

Subsection (g) of section 2 of the Stem Cell Therapeutic and Research Act of 2005 (42 U.S.C. 274k note) is amended to read as follows:

(g)

Authorization of appropriations

To carry out this section, there is authorized to be appropriated $23,000,000 for each of fiscal years 2020 through 2024.

.